SBOT GO

Germline Pathogenic Variants AmongWomenWithout a History of Breast Cancer A Secondary Analysis of the WISDOM Randomized Clinical Trial

Pooled analysis by best confirmed response to trastuzumab deruxtecan andrelated biomarkers in patients with HER2-positive metastatic breast cancerfrom DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03